Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer
and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of …

Background: The cost-effectiveness of screening the US population for Centers for Disease
Control and Prevention (CDC) Tier 1 genomic conditions is unknown. Objective: To estimate …

PURPOSE To determine the sensitivity and specificity of genetic testing criteria for the
detection of germline pathogenic variants in women with breast cancer. MATERIALS AND …

Importance Genomic screening for hereditary breast and ovarian cancer (HBOC) in
unselected women offers an opportunity to prevent cancer morbidity and mortality, but the …

Predictive genetic testing can provide information about whether or not someone will
develop or is likely to develop a specific condition at a later stage in life. Economic …

Background The use of proactive genetic screening for disease prevention and early
detection is not yet widespread. Professional practice guidelines from the American College …

PURPOSE To determine the contribution of germline pathogenic variants (PVs) in hereditary
cancer testing panel genes to invasive lobular carcinoma (ILC) of the breast. MATERIALS …

Objective To determine the feasibility of universal genetic testing of women with newly
diagnosed breast cancer, to estimate the incidence of pathogenic gene variants and their …

Importance Pathogenic variants (PVs) inBRCA1, BRCA2, PALB2, RAD51C, RAD51D, and
BRIP1cancer susceptibility genes (CSGs) confer an increased ovarian cancer (OC) risk …